Treatment With Nandrolone Decanoate and Megestrol Acetate in HIV-Infected Men

Abstract

Background: Malnutrition, especially loss of lean body mass, is a frequent complication of people living with HIV that may increase their mortality and morbidity. Methods: Nine HIV-infected men with unexplained loss of >10% of their usual weight were selected. They received megestrol acetate (MA) (400 mg/day by mouth) and nandrolone decanoate (ND) (100 mg/15 days intermuscular injection) over 16 weeks. Anthropometric evaluations, bioelectrical impedance, grip strength dynamometry, hematologic, biochemical, immunological and hormonal analysis before, during, and after the treatment were performed. Quality of life was evaluated by the Karnofsky index. Results: In the 7 men that finished the treatment, there were significant increases in weight (11.9 ± 9.1 kg, p < .05), 4-site skinfold measurements (p < .05), midarm circumference (p < .005), and fat-free mass (FFM) (5.1 ± 4.1 kg, p < .05). The increase in fat mass was not statistically significant (6.9 ± 6.4 kg, NS). Muscle strength increased significantly (p < .005). The Karnofsky index values increased from 59% to 73% (p < .05). One patient developed mild hyperglycemia and another one had an increase in aspartate transaminase and γ-glutamyl transpeptidase that reversed after the treatment. Four patients developed asymptomatic adrenal suppression. Testosterone serum levels decreased significantly during the study (p < .05), and 4 patients had serum values below the normal range at week 16. One patient developed gynecomastia. Conclusions: The combined treatment with MA and ND led to a significant increase in body weight and FFM. Muscle strength and quality of life improved during the study. The treatment was well tolerated with mild side effects.

Get full access to this article

View all access options for this article.

References

Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000 ;31:803– 805.

Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:230– 236.

Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989 ;50:444– 447.

Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(suppl):S69– S78.

Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol. 1998 ;25:104– 111.

Schwenk A, Bürger B, Ollenschläger G, et al. Evaluation of nutritional counselling in HIV-associated malnutrition. Clin Nutr. 1994;13:212– 220.

Schwenk A, Steuck H, Kremer G. Oral supplements as adjunctive treatment to nutritional counseling in malnourished HIV-infected patients: randomized controlled trial. Clin Nutr. 1999 ;18:371– 374.

Kotler DP, Tierney AR, Ferraro R, et al. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr. 1991 ;53:149– 154.

Melchior JC, Chastang C, Gelas P, et al. Efficacy of 2-month total parenteral nutrition (TPN) in AIDS patients: a controlled randomized prospective trial. AIDS. 1996 ;10:379– 384.

10.

Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994 ;121:400– 408.

11.

Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997 ;14:7– 14.

12.

Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2:692– 699.

13.

Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS. 1996;10:745– 752.

14.

Earthman CP, Reid PM, Harper IT, Ravussin E, Howell WH. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenter Enteral Nutr. 2002 ;26:357– 365.

15.

Hengge UR, Stocks K, Wiehler H, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS. 2003 ;17:699– 710.

16.

Grinspoon S, Gelato M. Editorial: the rational use of growth hormone in HIV-infected patients. J Clin Endocrinol Metab. 2001;86:3478– 3479.

17.

Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996 ;125:865– 872.

18.

Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000 ;16:1345– 1355.

19.

Ockenga J, Rhode F, Suttmann U, Herbarth L, Ballmaier M, Schedel I. Ketotifen in HIV-infected patients: effects on body weight and release of TNF-alpha. Eur J Clin Pharmacol. 1996;50 : 167–170.

20.

Roubenoff R, McDermott A, Weiss L, et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS. 1999 ; 13:231– 239.

21.

Von Roenn J, Armstrong D, Kothler DP. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994 ;121:393– 399.

22.

Heymsfield SB, Baumgartner RN, Pan SF. Nutritional assessment of malnutrition by anthropometric methods. In: Shils ME, Olson JA, Shike M, et al, eds. Modern Nutrition in Health and Disease. 9^th ed., Baltimore, MD: Williams & Wilkins; 1999:903– 921.

23.

Durnin JVGA, Womersley J. Body fat assessment from total body density and its estimation from skinfold thickness measurements on 481 men and women aged 16–72 years. Br J Nutr. 1974 ; 32:77– 97.

24.

Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr. 1994;7:46– 51.

25.

Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81:4051– 4058.

26.

Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis. 2000 ;31:1240– 1244.

27.

Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate on body composition and circulating testosterone concentrations in patients with AIDS. AIDS. 1995 ;9:1107– 1108.

28.

Dobs AS, Few WL, Blackman MR, Harman SM, Hoover DR, Graham NM. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab. 1996;81 :4108– 4112.

29.

Grinspoon S, Corcoran C, Anderson E, et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis. 1999 ;28:634– 636.

30.

Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23:1355– 1390.

31.

Kopera H. Anabolic steroids in deficiency states. In: Kopera H, ed. Anabolic-Androgenic Steroids: Towards 2000. Vienna: Blackwell-MZV; 1993:225– 226.

32.

Van Loan MD, Strawford A, Jacob M, Hellerstein M. Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy. AIDS. 1999;13:241– 248.

33.

Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 ;20:137– 146.

34.

Sattler FR, Jaque SV, Schroeder ET, et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1999 ;84:1268– 1276.

35.

Sattler FR, Schroeder ET, Dube MP, et al. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Am J Physiol Endocrinol Metab. 2002 ;283:E1214– E1222.

36.

Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl. 2001 ;24:232– 240.